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INTRODUCTION
Malaria is one of the disastrous health problem for
most of the regions of the world, specifically in endemic
regions like India and Africa. In 2010, WHO estimated
that 219 million cases were registered for malaria and
among those 90% were caused due to Plasmodium
falciparum alone over worldwide1. There are various other
species of Plasmodium infecting cattle, birds, and humans,
but mainly there are four species—P. falciparum, P. vivax,
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ABSTRACT
Background & objectives: Cysteine proteases (falcipains), a papain-family of enzymes of Plasmodium falciparum,
are responsible for haemoglobin degradation and thus necessary for its survival during asexual life cycle phase
inside the human red blood cells while remaining non-functional for the human body. Therefore, these can act as
potential targets for designing antimalarial drugs. The P. falciparum cysteine proteases,  falcipain-II  and falcipain-
III are the enzymes which  initiate the haemoglobin degradation, therefore, have been  selected as  targets. In the
present study, we have designed new leupeptin analogues and subjected to virtual screening using Glide at the
active site cavity of falcipain-II and falcipain-III to select the best docked analogues on the basis of Glide score
and also compare with the result of AutoDock. The proposed analogues can be synthesized and tested in vivo as
future potent  antimalarial drugs.
Methods: Protein falcipain-II and falcipain-III together with bounds inhibitors epoxysuccinate E64 (E64) and
leupeptin respectively were retrieved from protein data bank (PDB) and latter leupeptin was used as lead molecule
to design new analogues by using Ligbuilder  software and refined the molecules on the basis of Lipinski rule of
five and fitness score parameters.  All the designed leupeptin analogues were screened via docking simulation at
the active site cavity of falcipain-II and falcipain-III by using Glide software and AutoDock.
Results: The 104 new leupeptin-based antimalarial ligands were designed using structure-based drug designing
approach with the help of Ligbuilder and subjected for virtual screening via docking simulation method against
falcipain-II and falcipain-III receptor proteins. The Glide docking results suggest that the ligands namely result_037
shows good binding and other two, result_044 and result_042 show nearly similar binding than naturally occurring
PDB bound ligand E64 against falcipain-II and in case of falcipain-III, 15 designed leupeptin analogues having
better binding affinity compared to the PDB bound inhibitor of falcipain-III. The docking simulation results of
falcipain-III with designed leupeptin analogues using Glide compared with AutoDock and find 80% similarity as
better binder than leupeptin.
Interpretation & conclusion: These results further highlight new leupeptin analogues as promising future inhibitors
for chemotherapeutic prevention of malaria. The result of Glide for falcipain-III has been compared with the
result of AutoDock and finds very less differences in their order of binding affinity. Although there are no extra
hydrogen bonds, however, equal number of hydrogen bonds with variable strength as compared to leupeptin
along with the enhanced hydrophobic and electrostatic interactions in case of analogues supports our study that it
holds the ligand molecules strongly within the receptor. The comparative e-pharmacophoric study also suggests
and supports our predictions regarding the minimum features required in ligand molecule to behave as falcipain-
III inhibitors and is also helpful in screening the large database as future antimalarial inhibitors.
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P. malariae and P. ovale in particular considered impor-
tant as these species infect humans2, 3. One of the main
causes for the comeback of malaria is due to resistance
against the most frequent and widely used drug against
malaria, e.g. mefloquine and chloroquine. The reason has
been attributed to the decreased susceptibility of resis-
tance transporters, PfCRT4 for chloroquine and PfMDR1
for multidrug resistance5. Artemisinin is being used at
present as the sole antimalarial6.  Plasmodium life cycle
is completed through many morphologically changes, J Vector Borne Dis 50, June 2013 94
which alternate between an invertebrate and vertebrate
host. Haemoglobin metabolism is one of the key for meta-
bolic processes for the survival of the parasite in its hu-
man blood stages.
There are several proteases involved in the degrada-
tion of host erythrocyte haemoglobin inside the special-
ized acidic food vacuole (pH 5–6) of the parasite. To ob-
tain some of the nutrients required for intra-erythrocytic
growth the parasites digests 25–75% of the host cell hae-
moglobin, liberating free amino acids for incorporation
into parasite proteins7. Aminopeptidases catalyse the
cleavage of amino acids from the amino-termini of pro-
tein or peptide substrates8. Due to emergence of resis-
tance against several antimalarial drugs it is utmost im-
portance to keep searching for new drugs and drug
combinations to inhibit the growth of protozoa. This re-
quires work on novel molecular targets in Plasmodium
and designing inhibitors with potential parasiticidal
activities. To date several drug targets have been identi-
fied by the sequencing of P. falciparum genome.
However, as far as availability of new drugs for malaria
is concerned, it has to be based on new biological target
proteins.
The potential antimalarial drug targets can be broadly
divided into three types, haemoglobin degradation en-
zymes, signaling and transport protein factors.  Within
the digestive vacuole haemoglobin is initially degraded
by aspartic proteases (plasmepsins I, II, and possibly
III and IV)9. The cysteine proteases (falcipains I, II and
III)10, 11, further degrade the plasmepsins digested prod-
ucts and the generated short peptides finally digested by
the metalloprotease (falcilysin). Apart from this falcipain-
II enzyme also degrades the erythrocyte-membrane skel-
etal proteins which include ankyrin and the band 4.1 to
destabilize the erythrocyte membrane which leads to the
release of the mature merozoites followed by host cell
rupture12. The synthesis of falcipain-II  occurs during the
trophozoite stage as a proenzyme (484 amino acid resi-
dues) and bound with membrane. This proenzyme is fi-
nally transported to the food vacuole via endoplasmic
reticulum/golgi system. During transportation process of
falcipain-II the N-terminal membrane anchored with 243
residues are proteolytically removed13, 14.
The ratio of concentration of falcipain-II is 1.8 times
higher than falcipain-III concentration in trophozoites
stage. The cleaving capacity of falcipain-III is nearly twice
as falcipain-II for haemoglobin. This shows the relative
contribution of both enzymes equally in haemoglobin deg-
radation and suggests probable targets for novel antima-
larial drug designing15. The significance of falcipain-II
and falcipain-III in the Plasmodium life cycle and the pres-
ence of X-ray crystal structure data make both the se-
lected proteins as ideal targets for antimalarial therapy
using new approaches in rational drug design. In the
present study, falcipain-II and falcipain-III have been se-
lected as the targets for designing of novel potent antima-
larial drugs for future use with the application of struc-
ture-based drug designing approach which includes the
application of Lipinski rule of five16, pharmacophore
modeling, virtual screening and docking simulation.
This study knowledge, the possibility of inhibition
activity shown by PDB bound natural falcipains inhibi-
tors leads us to design the novel derivatives as probable
antimalarial moieties by selecting more than one similar
target for small group of designed inhibitors. The objec-
tive of present work was to design novel antimalarial de-
rivatives by generating key interaction site and receptor-
based pharmacophore for already bound leupeptin order
to generate its analogues leading to better inhibitors for
deadly disease malaria.
MATERIAL & METHODS
Ligbuilder
This is a genetic algorithm-based tool to design new
ligands using  structure-based drug designing approach.
It uses the known bound inhibitors available in PDB in
X-ray crystallized structure or in complex form as a seed
molecule. Ligbuilder makes the target protein rigid for
running the pocket module to generate key functional fea-
tures and suggests pharmacophore model for interaction
between inhibitor and active site residues. The derived
pharmacophore model consists of pharmacophore features
and the internal distances between them. For getting the
good pharmacophore model the minimal distance between
any two pharmacophore features is not to be less than
3 Å and this number ranges between 3 and 8. The frag-
ment of known inhibitors used as building block to de-
velop new ligand molecules by linking or growing strat-
egy for all the molecules originated from a “seed”
structure, developed and evolved with a genetic algorithm.
The resultant molecules are filtered by using drug-like-
ness parameter and fitness score, based on chemical vi-
ability and binding affinity17.
LigPrep
It is used for optimization of ligands by generating
accurate, chemically corrected, energy minimized 3-D
molecular structures supplied with Schrödinger suite.
LigPrep optionally expands the ligand to its different form
(tautomeric, ionization states, ring conformations and ste-
reoisomers) from single input of ligand structure18. 95 Kesharwani et al: In silico designing of antimalarial drugs by targeting falcipain-III
QikProp
This is module of Schrödinger suite to screen the small
data according to descriptor parameter and prediction of
ADMET which also includes rule of five19.
Glide
It is docking simulation module supplied by
Schrödinger suite. Glide performs the exhaustive search
employing hierarchical filter for finding most favourable
interaction between one or more ligand molecules and a
receptor (protein or protein with cofactor). Receptor-grid
files were generated after preparing correct forms of pro-
teins and ligands using receptor-grid generation program
(shipped by Schrödinger). For grid generation potential
of non-polar parts of receptor was softened by scaling
van der Waals radii of ligand atoms by 1.00 Å with par-
tial charge cut-off of 0.25. It is having all types of option
of speed vs accuracy.  It is having three mode of docking,
high-throughput virtual screening (HTVS), standard pre-
cision (SP), and  extra precision (XP)  mode. The XP
mode is used for exhaustive sampling and advanced scor-
ing, resulting in even higher enrichment20.
Target and ligand selection
The target selection was based on the importance of
falcipain-II and falcipain-III proteins together with feasi-
bility due to presence of 3-D structure of X-ray crystal-
lized form of P. falciparum falcipain enzymes in PDB.
The 3-D structures of falcipain-II and falcipain-III were
retrieved with PDB ID: 3BPF, and 3BPM with resolu-
tion: 2.90 and 2.50 Å respectively. The downloaded pro-
tein falcipain-II having four chains (A, B, C, and D), four
epoxysuccinate E64 (molecular formula: C15H30N5O5) as
an inhibitor on each chain, 42 water of crystallization and
one  glycerol molecule17. Whereas the 3-D structure of
falcipain-III having two chains (A and B), two leupeptins
(Fig. 1) (molecular formula: C20H40N6O4) as an inhibitor
on each chain, 76 water of crystallization and 5 SO4 mol-
ecules as cofactor21. The two sets of ligands were designed
by using Ligbuilder on receptor falcipain-III and selected
for present study on the basis of   their fitness score in
comparison with leupeptin.
Ligand and target preparation
Both the sets of ligands were screened for ADMET
using QikProp and optimized by using LigPrep module
by generating different possible structural conformation
of ligands and it creates a library of 1500 conformation
for each ligand set. For optimization and energy minimi-
zation it uses OPLS-2005 force field. The target protein
was prepared by deleting the bound  cofactors, inhibitors
and surrounding water molecules together with the  addi-
tion of the  side chain atoms followed by optimization
and energy minimization.
Receptor grid generation and docking
The prepared protein was used as an input file for
generating the receptor grid file, which is used as input
file for docking simulation. During docking simulation
using different module of Schrödinger suite, potential of
non-polar parts of ligands was softened by scaling van
der Waals radii of ligand atoms by 0.8 Å with partial
charge cut-off of 0.15. During docking simulation, Glide
first places the centre of ligand at various grid positions
of a 1 Å grid and then by rotating ligand in all the Euler
angles it generates various possible conformations which
pass through a filter series composed of initial rough po-
sitioning followed by scoring phase. The docking simu-
lation was performed by allowing flexible torsions in
ligands with the use of XP mode, highly robust and very
accurate. The parameter selected for docking run was
default and a model energy function named Glide score
(Gscore) is used which combines force field and empiri-
cal terms for selecting the best docking pose, generated
as output.
Gscore = a* vdW + b* Coul + Lipo + Hbond + Metal + BuryP +
RotB + Site
Where, vdW is van der Wall energy; Coul is Cou-
lomb energy; Lipo is lipophilic contact term; Hbond rep-
resents hydrogen-bonding term; Metal is metal-binding
term; BuryP is penalty for buried polar groups; RotB rep-
resents penalty for freezing rotatable bonds; Site is
polar interactions at the active site; and a, b representing
coefficients of vdW and Coul are set as: a = 0.065; and
b = 0.130.
The molecular docking simulations output file, hav-
ing all the thermodynamics information in the form of Fig. 1: 2-D structure of leupeptin. J Vector Borne Dis 50, June 2013 96
Glide score, were analyzed using Glide XP visualizer,
which enables visualization of ligand-receptor interactions
in an interactive manner.
In the case of docking simulation using AutoDock,
input files were prepared using MglTools and AutoGrid
modules. AutoGrid generates grid files for each atom
types found in ligand molecules. For docking purpose
ligands single bonds are allowed to rotate freely and Lama-
rckian genetic algorithm has been used. The grid box limit
as 90 × 90 × 90 points and grid spacing 0.375Å was
chosen22.
E-pharmacophore hypothesis generation
It is the hybrid approach of ligand and structure-based
technique which uses docking energy score for finding
the bioactive component of ligands against the receptor.
For the generation of energy-based pharmacophore (e-
pharmacophore) docking post-processing module of script
option was selected and input file given in .xpdes format.
E-pharmacophore was generated by using all the default
chemical features [hydrogen bond acceptor (A), hydro-
gen bond donor (D), hydrophobe (H), aromatic ring (R),
positive ionizable (P), and negative ionizable (N)]23.
RESULTS & DISCUSSION
Designing of leupeptin analogues at the active site cavity
of receptor falcipain-III
With the application of POCKET module of
Ligbuilder, the key interaction sites inside the binding
pocket could be visualized, where nitrogen atoms repre-
sent hydrogen-bond donor sites (Blue); oxygen atoms rep-
resent hydrogen-bond acceptor sites (Red); and carbon
atoms (Green) represent hydrophobic sites13. Based on
these observations a pharmacophore model was suggested
(Figs. 2 and 3 [a & b]). The 104 novel leupeptin ana-
logues were designed using two basic fragments of
leupeptin by defining growing points as shown in Fig. 4
(a & b).
Docking simulation
The objective of the present study was aimed at explor-
ing the interactions and binding affinity of leupeptin ana-
Fig. 2: Key interaction site for leupeptin at the active site of falcipain-
III protein (3bpm.pdb) in cartoon representation using Molegro
virtual docker.
Fig. 3: (a) Representation of key interaction site inside the binding
pocket of falcipain-III protein, together with leupeptin; and
(b) Derived pharmacophore model of leupeptin using
Ligbuilder and for visualization Molegro virtual docker was
used. 97 Kesharwani et al: In silico designing of antimalarial drugs by targeting falcipain-III
logues at the active site of falcipain-II and falcipain-III to
inhibit the process of haem digestion during asexual phase
of Plasmodium life cycle inside the human body. Results
of docking simulations using Glide are summarized as XP
Gscore, lipophilic energy, H-bond energy and electro-
phoretic energy along with residues involved in hydrogen
bond interactions and  in case of AutoDock3 as docked
energy (kcal/mol) and free energy for binding (kcal/mol).
Binding mode of designed leupeptin analogues and its
e-pharmacophore at the active site of falcipain-III
The leupeptin and its 104 designed  analogues   were
subjected to screening using XP level of Glide module
supplied by Schrödinger. The docking simulation results
show that the designed ligands have better binding affin-
ity than its natural inhibitor, leupeptin. Table 1 (a) shows
the list of 15 top scoring leupeptin analogues, and the
Table 1 (b) shows the top five analogues together with
Fig. 4: (a) Five growing points; and (b) Three growing points on basic fragments of leupeptin.
Table 1(a). The  top 15 molecules designed by Ligbuilder  having
highest binding energy score compared to leupeptin using Glide
S.No. Name of Gscore Lipophilic Hbond Electro-
ligand EvdW phoretic
1. result_037 –9.79 –5.29 –1.15 –0.71
2. result_035 –9.75 –5.36 –1.04 –0.72
3. result_036 –9.21 –4.45 –2.14 –0.94
4. result_045 –9.2 –4.43 –2.13 –0.95
5. result_033 –9.18 –5.07 –1.72 –0.72
6. result_030 –9.01 –4.41 –2.15 –1.07
7. result_042 –8.68 –3.8 –1.58 –0.55
8. result_005 –8.56 –3.12 –1.33 –0.68
9. result_041 –8.37 –4.19 –1.75 –0.83
10. result_046 –8.28 –4.5 –1.5 –0.79
11. result_043 –8.23 –4.01 –1.33 –0.89
12. result_009 –8.17 –4.32 –1.27 –0.54
13. result_002 –8.05 –4.25 –1.25 –0.51
14. result_032 –8.05 –4.15 –2.13 –1.23
15. result_003 –8.04 –3.08 –2.11 –0.75
16. leupeptin –5.52 –1.13 –1.49 –0.56
Table 1(b). Interaction of  Plasmodium falciparum falcipain-III protein residues  with top five designed
drug like molecules together with leupeptin
S.No. Ligands Residues of falcipain-III protein interacts with leupeptin analogues
1. result_037 Cys51, Gly91, Gly92, Ile94, Ser162, Asn182, His183, Trp215
2. result_035 Gly49, Cys51, Gly91, Gly92, Ile94, Ser162, Asn182, His183, Trp215
3. result_036 Cys51, Trp52, Tyr90, Gly91, Gly92, Asn182, His183
4. result_045 Gly49,  Tyr90, Gly91, Gly92, Tyr93, Asn182, His183
5. result_033 Gly49,  Cys51, Asn87, Gly91, Gly92, Tyr93,  Ser158, Asn182
6. leupeptin Gln45, Gly49,  Ser50, Cys51, Trp52, Tyr90, Gly91, Gly92, Tyr93, Asp164, Glu176, Asn182, His183
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Fig. 5: Cartoon view of falcipain-III protein showing top most 15
selected bound ligand structures using Molegro virtual docker.
Fig. 6 (a–e):Binding site conformation of result_037, result_035, result_036, result_045 and result_033 respectively docked to chain A of
falcipain-III protein (3bpm.pdb).
most common interacting residues of falcipain-III respon-
sible for stabilizing the complex.
Figurs 5 shows that all the leupeptin analogues are
bound at the same active site. On comparison of interact-
ing residues of the top five leupeptin analogues shows
that the amino acids Gly49, Cys51, Gly91, Gly92, Asn182
and His183 of falcipain-III protein are most commonly
involved.  Among these the residue Gly49 was the only
non-hydrogen bonding common interacting residue of
falcipain-III with ligands result_033, result_035, re-
sult_045 and leupeptin and all the remaining residues
participated in hydrogen bonding. Cys51 was the com-
mon hydrogen bonding interacting residue with ligands
result_033, result_036, result_037 and leupeptin [Table
1 (b); & Fig. 6 (a–e)]. The rest of the hydrogen bonding 99 Kesharwani et al: In silico designing of antimalarial drugs by targeting falcipain-III
residues (Gly91, Gly92, Asn182 and His183) of falcipain-
III participate with the top four leupeptin analogues to-
gether with leupeptin itself,   except residue His183, which
does not interact with ligand result_033. The docking
simulation result shows the participation of about 50%
active site residues of falcipain-III in the formation of
4–5 hydrogen bonds with leupeptin analogues to stabi-
lize the complex and provide force to inhibit the enzy-
matic action of falcipain-III for stopping the process of
haem degradation and finally killing of malaria parasite.
The e-pharmacophore was generated using docking
post-processing module. The e-pharmacophore was gen-
erated for single ligand result_037 having highest dock-
ing Gscore (–9.79) with maximum number of features
as 7 at the binding site of falcipain-III. The generated
e-pharmacophore are shown in Fig. 7 with two aromatic
rings  required for the hydrophobic interaction within the
pocket namely R14 (score –0.71) and other R13 (score
–0.66) together with three donor sites namely D4, D5 and
D6 having scores –0.62, –0.62 and –0.52 respectively.
One acceptor site A2 having score –0.22 has also been
shown. On comparing the pharmacophore generated
by Ligbuilder (Fig. 3b) and Schrödinger (Fig. 7) there is
clear cut similarity in relation to the presence of mini-
mum number of features, aromatic rings, donor and ac-
ceptor sites except one aromatic ring is less in Schrödinger
generated e-pharmacophore, this may be due to the
selection of different algorithms. The comparative
e-pharmacophoric study also suggests and supports our
predictions regarding the minimum features required
in ligand molecule to behave as falcipain-III inhibitors
and is helpful in screening the large database as future
antimalarials.
Binding mode of designed leupeptin analogues with
falcipain-II
Due to structural similarity of falcipain-II and
falcipain-III, the designed analogues were also tested
against falcipain-II for screening the compound effort to
find out if any leupeptin analogues having inhibition ac-
tivity against falcipain-II. The results obtained after dock-
ing simulation, 15 top most ligands have been selected
and found that only three leupeptin analogues are show-
ing activity nearly the bound inhibitor E64. The Glide
docking results suggest that the ligands, namely result_037
shows good binding and other two, result_044 and
result_042 show nearly similar binding than naturally
occurring PDB bound ligand E64 against falcipain-II. The
Fig. 7:   E-pharmacophore for result_037 at the active site of falcipain-III protein (3bpm.pdb). J Vector Borne Dis 50, June 2013 100
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Gscore of E64 and active leupeptin analogues are in
the order of  result_037 > E64 > result_044 > result_042
with Gscore –8.06, –7.94, –7.92,  and –7.91 respectively
(Table 2).
The docking simulation results of falcipain-III with
designed leupeptin analogues using Glide compared with
AutoDock and found 80% similarity as better binder than
leupeptin except slight difference in their order of Gscore.
In case of Glide, docking results for top five leupeptin
analogues are result_037 > result_035 > result_036 > re-
sult_045 > result_033 (Table 1a), and for AutoDock, the
order is result_030 > result_043 >  result_042 > result_037
> result_032 (Table 3). From Table 1(a) and Table 3 the
results suggest that these top five analogues are showing
better in silico inhibition activity against falcipain-III and
there activity varies slightly due to use of different dock-
ing softwares which follow different algorithm for simu-
lation study. Figure 8, shows the proposed leupeptin ana-
logues having better binding affinity than leupeptin itself
and could be used as antimalarial drugs after synthesis
and biological testing.
CONCLUSION
Falcipain-II and falcipain-III are reported as haem
degradation metabolizing enzymes responsible for initi-
ating the degradation of host erythrocyte haemoglobin
inside the food vacuole of the parasite. Since there are
limited number of drugs available to kill the Plasmodium
and always need to develop more anti-resistant antima-
larial drugs. In our present study, the results show better
binding affinity of leupeptin analogues as compared to
leupeptin itself at the active site of falcipain-III. Although
there are no extra hydrogen bonds, however, equal num-
ber of hydrogen bonds with variable strength as compared
to leupeptin along with the enhanced  hydrophobic and
electrostatic interactions in case of analogues supports
our study that it  holds the  ligand molecules strongly
within the receptor. The comparative e-pharmacophoric
study also suggests and supports our predictions
regarding the minimum features required in ligand mol-
ecule to behave as falcipain-III inhibitors and is helpful
in screening the large database as future antimalarial
inhibitors.
The docking results in case of falcipain-II the top three
leupeptin analogues showing about similar activity in the
form of Glide Score compare to bound ligand E64. The
similarity of target structures also suggests that there is
possibility of being targeted more than one by same group
of the inhibitors.  So the proposed inhibitors in future
could be either used alone or in combination with known
drugs which can together act synergistically more effec-
tively to treat malaria.
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Table 3.  Comparative docking simulation results of screened top
15 leupeptin analogues against  falcipain-III receptor
using AutoDock3 docking software
S.No. Name of Docked energy Free energy
ligands (kcal/mol) for binding
(kcal/mol)
1. result_030 –15 –9.39
2. result_043 –13.29 –8.8
3. result_042 –13.16 –8.42
4. result_037 –13.09 –9.86
5. result_032 –13.09 –8.75
6. result_045 –12.9 –8.83
7. result_036 –12.83 –8.93
8. result_046 –12.54 –8.5
9. result_035 –12.49 –9.39
10. result_002 –12.42 –8.4
11. result_041 –12.34 –8.9
12. result_009 –12.33 –8.73
13. leupeptine –11.84 –7.11
14. result_033 –11.78 –7.3
15. result_005 –11.45 –7.23
16. result_003 –11.09 –7.01
Table 2.  Comparative docking simulation results of in silico
screened top 15 leupeptin analogues as falcipain-II
inhibitors with the receptor falcipain-II as target
using Glide docking software
S.No. Name of Gscore Lipophilic Hbond Electro
ligand EvdW
1. result_037 –8.06 –5.39 –1.8 –0.87
2. E64 –7.94 –2.93 –4.45 –1.14
3. result_044 –7.92 –5.88 –1.71 –0.9
4. result_042 –7.91 –5.73 –1.86 –0.94
5. result_009 –7.3 –5 –1.55 –0.87
6. result_043 –7.3 –5.77 –1.52 –0.71
7. result_035 –6.96 –5.59 –1.17 –0.72
8. result_031 –6.89 –5.15 –2.03 –0.96
9. result_041 –6.39 –5.33 –0.94 –0.51
10. result_10 –6.34 –4.74 –1.43 –0.51
11. result_030 –6.24 –4.41 –1.47 –0.64
12. result_005 –5.84 –4.23 –1.49 –0.63
13. result_045 –5.48 –4.51 –1.43 –0.6
14. result_038 –5.47 –4.55 –0.94 –0.71
15. result_046 –5.43 –4.55 –1 –0.39
16. result_036 –5 –4.51 –1.26 –0.35 J Vector Borne Dis 50, June 2013 102
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